Medindia LOGIN REGISTER
Medindia
Advertisement

Legal Cannabis Sales Projected to Grow

Wednesday, March 15, 2017 Drug News
Advertisement
NEW YORK, March 15, 2017 /PRNewswire/ --
Advertisement

FinancialBuzz.com News Commentary 

Over the years, many states have legalized the use of cannabis products, for both medical and recreational purposes. As a result sales of such products grew overtime, and a new industry has been established. A report published on March 9th by New Frontier Data, a technology-driven analytics company specializing in the cannabis industry, reveals that the legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% to reach more than $24 billion by 2025. The projections are being made under the assumption that no new states will pass legalization legislations throughout the forecasted period. ChineseInvestors.com, Inc. (OTC: CIIX), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), United Cannabis Corporation (OTC: CNAB), MassRoots Inc. (OTC: MSRT)
Advertisement

CEO and Founder of New Frontier Data Giadha Aguirre De Carcer, commented, "Over the course of refining our market projections, there have been important lessons learned from each state's market performance, the industry's nuanced developments, and from the increased amount of data gathered from state regulatory agencies. We applaud, in particular, the work of Washington State which has set the gold standard in transparency by making all the data collected by its seed-to-sale system publicly available. This level of transparency is enormously valuable as it enables all stakeholders across the industry, including operators, investors, regulators and policymakers to have a quantifiable view into this highly dynamic industry."

ChineseInvestors.com, Inc. (OTCQB: CIIX) on February 13th, announced business achievements in January 2017. "January represents a significant milestone in CIIX's 18-year history, and we are pleased to update shareholders on key highlights of our progress. This includes sequential revenue growth and our entrance into the hemp-based CBD oil industry," says CIIX Founder and CEO, Warren Wang. He further added, "I am grateful for investors who support our ongoing development plans and look forward to a prosperous year ahead."

Earlier in February ChineseInvestors.com announced, "The launch of its new website for its new subsidiary ChineseCBDoil.com. The website went live on January 31st under the http://www.ChineseCBDoil.com. The company is expanding into the medical marijuana industry with the launch of its website and plans to retail hemp oil and related products, which are legal to sell and distribute within China and in the United States in all fifty states (hemp oil is not marijuana, but indeed a separate and distinct plant made from hemp). CBD oil, derived from hemp is a product with medicinal qualities that are primarily used for anti-inflammatory and other common ailments." 

Cara Therapeutics Inc. (NASDAQ: CARA) is focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed. Cara's most advanced compound, CR845, is currently undergoing clinical testing for acute pain, chronic pain and uremic pruritus (itch). In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. With well over 1000 subjects dosed to date, CR845 was found to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists.

Insys Therapeutics Inc. (NASDAQ: INSY) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients' lives. Using proprietary sublingual spray technology and our capabilities to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing commercial products. Earlier in February the company announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study. The long-term safety study permitted subjects who had completed the initial safety and pharmacokinetic (PK) study to receive Cannabidiol Oral Solution at doses up to 40 mg/kg/day for up to 48 weeks.

United Cannabis Corporation (OTCQB: CNAB) has signed an exclusive licensing agreement with Vessel Life Sciences to produce and distribute its products along with Prana Bio Nutrient Medicinal, throughout Pennsylvania. Prana Bio Medicinal products provide patients a simple, safe, accurate, and easy way to mix match cannabinoids for therapeutic purpose. These products are broken into 5 easy to use categories that are available in capsules, sublingual and topical delivery methods. The company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability. Prana Bio Medicinal products are NON-GMO, ethanol free, alcohol free, glycerin free, gluten free, 100% naturally derived, chemical-free, solvent less, and hypoallergenic.

MassRoots Inc. (OTCQB: MSRT) offers technology platforms for the cannabis industry. The Company's mobile applications enable consumers to provide community-driven reviews of cannabis strains and products, enabling consumers to make cannabis purchasing decisions. Through its mobile applications and web portal with over 900,000 users, members utilize MassRoots to share their cannabis content, stay connected with the legalization news and follow their preferred dispensaries. Its mobile application features dispensary finder and menus; product pages and reviews, and sponsored posts 2.0. It provides business dashboards featuring MassRoots' product data in actionable formats. The Company focuses on introducing other features for users and index the network's public content on Google for software engine optimization value. The Company gains insights into consumer trends by aggregating data from various cannabis consumers.

Please SIGN UP NOW at http://www.FinancialBuzz.com to receive alerts on trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com    

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use.

Please visit: http://www.financialbuzz.com

Media Contact: [email protected] +1-877-601-1879 http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close